PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License

Company Overview - PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA [4] - The company aims to alleviate the global backlog of generic, clinical-grade MDMA for clinical trials and commercial sales, while also developing novel drugs in the same class [4] - PharmAla is currently the only company provisioning clinical-grade MDMA for patient treatments outside of clinical trials [4] Recent Developments - PharmAla has completed customs clearance and delivered over 500 capsules of LaNeo 40mg MDMA to Merhavim Mental Health Centre in Israel [1] - The delivery is seen as a precedent for innovative terms that reduce financial risk for researchers while allowing PharmAla to develop intellectual property cost-effectively [2] - The clinical trial associated with this delivery focuses on "MDMA Assisted Psychotherapy for PTSD of Early Sexual Trauma Compared to All Trauma in Adulthood" [2] Research and Support - Researchers can access a tool for drug product quality information on PharmAla's website, facilitating the examination of the LaNeo MDMA Chemistry, Manufacturing, and Control package [3] - PharmAla is open to offering discounts for data sharing where appropriate, encouraging collaboration with qualified researchers [3] Strategic Partnerships - MAPS Israel, a non-profit organization focused on psychedelic research and public health education, is a partner in the clinical trial [2] - The collaboration aims to explore new mental health indications while navigating complexities in cross-border trade and regional conflicts [2] Future Outlook - PharmAla's research and development unit has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [4] - The company emphasizes the importance of maintaining excellent relationships with regulators to achieve success in the psychedelics industry [4]